+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
8 Apr 2018

Plaque psoriasis drug Tremfya receives Australian & Brazilian approvals

/
Posted By
/
Comments0
/

MorphoSys AG, a late-stage, biopharmaceutical company, announced that country subsidiaries of its licensee Janssen reported that Tremfya (guselkumab) has been approved for the treatment of adults living with moderate to severe plaque psoriasis in Brazil and Australia.

As reported by Janssen-Cilag Farmacêutica Ltda. (Janssen), the Brazilian National Health Surveillance Agency (ANVISA) has approved Tremfya for the treatment of adults living with moderate to severe plaque psoriasis. Janssen-Cilag Pty Limited (Janssen) announced that Tremfya has been approved by the Therapeutic Goods Administration (TGA) and registered on the Australian Register of Therapeutic Goods (ARTG) for the treatment of adults living with moderate to severe plaque psoriasis in Australia.

Tremfya is a fully human anti-IL-23 monoclonal antibody developed by Janssen and was generated utilizing MorphoSys’s proprietary HuCAL antibody library technology.

MorphoSys is eligible to receive royalties on net sales of Tremfya.

n addition to psoriasis, Tremfya is in phase 3 development in psoriatic arthritis. Janssen has announced plans to investigate guselkumab in Crohn’s disease.

MorphoSys is a late-stage, biopharmaceutical company devoted to the development of innovative and differentiated therapies for patients suffering from serious diseases.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.